Scarica l'app Stockscreener
3.165
7.18%
-0.245
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Cumberland Pharmaceuticals Inc Borsa (CPIX) Ultime notizie
Asthma Market to Expand Significantly by 2034, States - openPR.com
Asthma Market to Expand Significantly by 2034, States DelveInsight Report | GSK, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma, Genentech - Barchart.com
Two Sigma Investments LP Has $89,000 Stake in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) - Defense World
Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Cross Above Two Hundred Day Moving Average – Here’s Why - Defense World
Cumberland pharmaceuticals director Kenneth Krogulski acquires $4,824 in stock By Investing.com - Investing.com South Africa
Cumberland pharmaceuticals director Kenneth Krogulski acquires $4,824 in stock - Investing.com
Dilated Cardiomyopathy Market Witnesses Robust Growth During the Study Period (2020–2034) Amid Advancements in Cardiovascular Therapies | DelveInsight - GlobeNewswire Inc.
Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above 200 Day Moving Average – Time to Sell? - Defense World
Investors in Cumberland Pharmaceuticals (NASDAQ:CPIX) have seen splendid returns of 235% over the past year - Yahoo
NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS - PR Newswire
Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why - Defense World
Q&A: Cumberland Pharmaceuticals CEO A.J. Kazimi weighs in on industry challenges, strengths - The Business Journals
Cumberland CEO A.J. Kazimi: Pharmaceutical tariffs would be 'concerning' - The Business Journals
Dimensional Fund Advisors LP Cuts Stock Position in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) - Defense World
Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025 - The Victoria Advocate
Cumberland, Qureight Collaborate on Lung Disease Treatment Trial - marketscreener.com
CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH - PR Newswire
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q1 2025 Earnings Call Transcript - Insider Monkey
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Held Back By Insufficient Growth Even After Shares Climb 30% - simplywall.st
Cumberland Pharmaceuticals Leverages AI Technology to Transform IPF Treatment Research in Major Clinical Trial - Stock Titan
Cumberland Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks
Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Rating Upgraded by StockNews.com - Defense World
Cumberland Pharmaceuticals Reports Strong Q1 2025 Growth - TipRanks
Cumberland Pharmaceuticals Inc (CPIX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Cumberland: Q1 Earnings Snapshot - MySA
Cumberland Pharmaceuticals Inc Reports Q1 2025 Earnings: EPS at $0.16, Revenue Hits $11.7 Million - GuruFocus
Earnings call transcript: Cumberland Pharmaceuticals sees Q1 2025 revenue jump 38% - Investing.com
Cumberland Pharmaceuticals Inc.Common Stock (NQ: CPIX - FinancialContent
Renaissance Technologies LLC Sells 21,000 Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) - Defense World
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE - marketscreener.com
Cumberland Pharmaceuticals Q1 Earnings Call: Key Updates from Specialty Drug Portfolio Coming May 6 - Stock Titan
Cumberland Pharmaceuticals Shareholders Approve Key Proposals By Investing.com - Investing.com India
Cumberland Pharmaceuticals Shareholders Approve Key Proposals - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Cumberland Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Cumberland Pharmaceuticals' (NASDAQ:CPIX) growing losses don't faze investors as the stock swells 18% this past week - simplywall.st
Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Crosses Above 200 Day Moving Average – Here’s Why - Defense World
Cumberland Pharmaceuticals director Caroline Young acquires $383 in common stock - Investing.com Australia
Cumberland Pharmaceuticals director Kenneth Krogulski acquires $4,548 in stock By Investing.com - Investing.com South Africa
Cumberland Pharmaceuticals director James Jones buys shares worth $880 By Investing.com - Investing.com South Africa
Cumberland Pharmaceuticals director Kenneth Krogulski acquires $4,548 in stock - Investing.com
Cumberland Pharmaceuticals CEO A.J. Kazimi acquires $880 in common stock - Investing.com
Cumberland Pharmaceuticals director James Jones buys shares worth $880 - Investing.com India
Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Passes Above 200 Day Moving Average – What’s Next? - Defense World
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
FIGHT DMD trial results selected for late-breaking presentation at MDA clinical & scientific conference - Marketscreener.com
Breakthrough DMD Heart Disease Treatment Achieves 5.4% Function Boost While Controls Decline - Stock Titan
FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference - PR Newswire
0.27%
0.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):